OncoMatch/Clinical Trials/NCT05083754
Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma
Is NCT05083754 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including Retifanlimab and Temozolomide for glioblastoma multiforme.
Treatment: Retifanlimab · Temozolomide — The purpose of the study is to evaluate the safety and survival of carmustine wafers and radiation and retifanlimab with or without temozolomide (TMZ) in newly-diagnosed adult subjects with glioblastoma multiform after carmustine wafer placement.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Cancer type
Glioblastoma
Disease stage
Required: Stage IV
Grade: iv (who)
Demographics
Prior therapy
Must have received: surgical resection
No prior treatment for GBM other than surgical resection and carmustine wafer placement
Must have received: carmustine wafer
carmustine wafers placed at resection
Cannot have received: anti-PD-1 therapy
Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, anti-CTLA-4 antibody or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways
Cannot have received: other anti-neoplastic medications/treatments including the Optune® device
Intent to use other anti-neoplastic medications/treatments including the Optune® device
Lab requirements
Blood counts
Must have normal organ and marrow function on routine laboratory tests
Kidney function
Must have normal organ and marrow function on routine laboratory tests
Liver function
Must have normal organ and marrow function on routine laboratory tests
Must have normal organ and marrow function on routine laboratory tests
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Johns Hopkins Medical Institution · Baltimore, Maryland
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05083754 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage IV is required.
Is there an age limit?
Yes. Patients must be 100 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages